$206.40
-0.24-0.12%
Last update: 9:49 AM
15 minutes delayed
Comments
Loading...
Krystal Biotech
KRYSNASDAQ
Unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Krystal Biotech (NASDAQ:KRYS) Stock, Analyst Ratings, Price Targets, Forecasts
Krystal Biotech Inc has a consensus price target of $170.55 based on the ratings of 11 analysts. The high is $204 issued by Stifel on April 16, 2024. The low is $140 issued by B of A Securities on May 25, 2023. The 3 most-recent analyst ratings were released by HC Wainwright & Co. on May 8, 2024, May 6, 2024, and April 22, 2024, respectively. With an average price target of $200 between HC Wainwright & Co., there's an implied -3.21% downside for Krystal Biotech Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
HC Wainwright & Co.
Stifel
Citigroup
Guggenheim
Cantor Fitzgerald
1calculated from analyst ratings
Analyst Ratings for Krystal Biotech
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 05/08/2024 | Buy Now | -3.21% | HC Wainwright & Co. | Joseph Pantginis | → $200 | Reiterates | Buy → Buy | Get Alert |
| 05/06/2024 | Buy Now | -3.21% | HC Wainwright & Co. | Joseph Pantginis | → $200 | Reiterates | Buy → Buy | Get Alert |
| 04/22/2024 | Buy Now | -3.21% | HC Wainwright & Co. | Joseph Pantginis | → $200 | Reiterates | Buy → Buy | Get Alert |
| 04/16/2024 | Buy Now | -1.28% | Stifel | Dae Gon Ha | $178 → $204 | Reiterates | Buy → Buy | Get Alert |
| 02/27/2024 | Buy Now | -5.63% | Citigroup | Yigal Nochomovitz | $160 → $195 | Maintains | Buy | Get Alert |
| 02/27/2024 | Buy Now | -15.31% | Guggenheim | Debjit Chattopadhyay | $130 → $175 | Maintains | Buy | Get Alert |
| 12/13/2023 | Buy Now | -12.89% | Cantor Fitzgerald | Josh Schimmer | $160 → $180 | Maintains | Overweight | Get Alert |
| 11/20/2023 | Buy Now | -22.57% | Goldman Sachs | Andrea Tan | → $160 | Initiates | → Buy | Get Alert |
| 11/07/2023 | Buy Now | -22.57% | Cantor Fitzgerald | Josh Schimmer | → $160 | Reiterates | Overweight → Overweight | Get Alert |
| 10/24/2023 | Buy Now | -22.57% | Cantor Fitzgerald | Josh Schimmer | → $160 | Initiates | → Overweight | Get Alert |
| 10/12/2023 | Buy Now | -22.57% | Citigroup | Carly Kenselaar | → $160 | Initiates | → Buy | Get Alert |
| 09/07/2023 | Buy Now | -25.47% | Berenberg | Caroline Palomeque | → $154 | Initiates | → Buy | Get Alert |
| 08/08/2023 | Buy Now | -25.96% | Chardan Capital | Geulah Livshits | $148 → $153 | Maintains | Buy | Get Alert |
| 08/07/2023 | Buy Now | -32.73% | HC Wainwright & Co. | Joseph Pantginis | → $139 | Reiterates | Buy → Buy | Get Alert |
| 07/27/2023 | Buy Now | -32.73% | HC Wainwright & Co. | Joseph Pantginis | → $139 | Reiterates | Buy → Buy | Get Alert |
| 07/03/2023 | Buy Now | -32.73% | HC Wainwright & Co. | Joseph Pantginis | → $139 | Reiterates | → Buy | Get Alert |
| 05/25/2023 | Buy Now | -32.25% | B of A Securities | Alec Stranahan | $118 → $140 | Maintains | Buy | Get Alert |
| 05/24/2023 | Buy Now | -29.83% | Stifel | Dae Gon Ha | $102 → $145 | Maintains | Buy | Get Alert |
| 05/22/2023 | Buy Now | -37.09% | Guggenheim | Debjit Chattopadhyay | $101 → $130 | Maintains | Buy | Get Alert |
| 05/22/2023 | Buy Now | -24.99% | Goldman Sachs | Madhu Kumar | $135 → $155 | Maintains | Buy | Get Alert |
| 05/22/2023 | Buy Now | -28.38% | Chardan Capital | Geulah Livshits | $133 → $148 | Maintains | Buy | Get Alert |
| 05/22/2023 | Buy Now | -32.73% | HC Wainwright & Co. | Joseph Pantginis | $119 → $139 | Maintains | Buy | Get Alert |
| 05/22/2023 | Buy Now | -42.9% | B of A Securities | Alec Stranahan | $105 → $118 | Maintains | Buy | Get Alert |
| 05/07/2023 | Buy Now | -34.67% | Goldman Sachs | Madhu Kumar | → $135 | Maintains | Buy | Get Alert |
| 04/18/2023 | Buy Now | -50.64% | Stifel | Dae Gon Ha | → $102 | Initiates | → Buy | Get Alert |
| 02/28/2023 | Buy Now | -51.12% | Guggenheim | Debjit Chattopadhyay | → $101 | Reiterates | → Buy | Get Alert |
| 02/28/2023 | Buy Now | -42.41% | HC Wainwright & Co. | Joseph Pantginis | → $119 | Reiterates | → Buy | Get Alert |
| 02/28/2023 | Buy Now | -39.99% | Goldman Sachs | Madhu Kumar | $79 → $124 | Upgrade | Neutral → Buy | Get Alert |
| 02/28/2023 | Buy Now | -35.64% | Chardan Capital | Geulah Livshits | → $133 | Reiterates | → Buy | Get Alert |
| 11/08/2022 | Buy Now | -35.64% | Chardan Capital | Geulah Livshits | $130 → $133 | Maintains | Buy | Get Alert |
| 11/07/2022 | Buy Now | -61.77% | Goldman Sachs | Madhu Kumar | $74 → $79 | Maintains | Neutral | Get Alert |
| 11/07/2022 | Buy Now | -42.41% | HC Wainwright & Co. | Joseph Pantginis | $107 → $119 | Maintains | Buy | Get Alert |
| 08/25/2022 | Buy Now | -64.19% | Goldman Sachs | Madhu Kumar | → $74 | Downgrade | Buy → Neutral | Get Alert |
| 08/09/2022 | Buy Now | -37.09% | Chardan Capital | Geulah Livshits | $137 → $130 | Maintains | Buy | Get Alert |
| 08/08/2022 | Buy Now | -64.19% | Goldman Sachs | Madhu Kumar | $78 → $74 | Maintains | Buy | Get Alert |
| 05/24/2022 | Buy Now | -62.25% | Goldman Sachs | Madhu Kumar | $91 → $78 | Maintains | Buy | Get Alert |
| 03/01/2022 | Buy Now | -54.99% | Goldman Sachs | Madhu Kumar | $125 → $93 | Maintains | Buy | Get Alert |
| 02/28/2022 | Buy Now | -48.22% | HC Wainwright & Co. | Joseph Pantginis | $124 → $107 | Maintains | Buy | Get Alert |
| 01/18/2022 | Buy Now | -46.77% | B of A Securities | Alec Stranahan | → $110 | Initiates | → Buy | Get Alert |
| 11/30/2021 | Buy Now | -39.99% | HC Wainwright & Co. | Joseph Pantginis | $103 → $124 | Maintains | Buy | Get Alert |
| 11/29/2021 | Buy Now | -39.51% | Goldman Sachs | Madhu Kumar | $85 → $125 | Maintains | Buy | Get Alert |
| 11/29/2021 | Buy Now | -39.99% | HC Wainwright & Co. | Joseph Pantginis | $103 → $124 | Maintains | Buy | Get Alert |
| 08/09/2021 | Buy Now | -57.9% | Goldman Sachs | Madhu Kumar | $90 → $87 | Maintains | Buy | Get Alert |
FAQ
What is the target price for Krystal Biotech (KRYS) stock?
The latest price target for Krystal Biotech (NASDAQ:KRYS) was reported by HC Wainwright & Co. on May 8, 2024. The analyst firm set a price target for $200.00 expecting KRYS to fall to within 12 months (a possible -3.10% downside). 15 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Krystal Biotech (KRYS)?
The latest analyst rating for Krystal Biotech (NASDAQ:KRYS) was provided by HC Wainwright & Co., and Krystal Biotech reiterated their buy rating.
When was the last upgrade for Krystal Biotech (KRYS)?
The last upgrade for Krystal Biotech Inc happened on February 28, 2023 when Goldman Sachs raised their price target to $124. Goldman Sachs previously had a neutral for Krystal Biotech Inc.
When was the last downgrade for Krystal Biotech (KRYS)?
The last downgrade for Krystal Biotech Inc happened on August 25, 2022 when Goldman Sachs changed their price target from N/A to $74 for Krystal Biotech Inc.
When is the next analyst rating going to be posted or updated for Krystal Biotech (KRYS)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Krystal Biotech, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Krystal Biotech was filed on May 8, 2024 so you should expect the next rating to be made available sometime around May 8, 2025.
Is the Analyst Rating Krystal Biotech (KRYS) correct?
While ratings are subjective and will change, the latest Krystal Biotech (KRYS) rating was a reiterated with a price target of $200.00 to $200.00. The current price Krystal Biotech (KRYS) is trading at is $206.40, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.